Cel-SCI Corporation Announces Common Stock Offering
Vienna, Virginia, July 11, 2025 – Cel-SCI Corporation, a clinical-stage immunotherapy company for cancer treatment, has revealed a Best Effort pricing initiative to offer 1,500,000 shares of common stock. Each share is priced at $3.82 under NYSE American guidelines. The total revenue from this offering is anticipated to be around $5.7 million before any deductions for fees or costs associated with the offering. The recruitment phase is expected to wrap up on July 14, 2025, following the usual closing conditions.
The company intends to allocate the net proceeds from this offering towards the development of Multikine, along with general corporate purposes and working capital needs.
Thinkequity is the sole deployment agent overseeing this offering.
The shares are being sold under a shelf registration statement on Form S-3, which includes a basic prospectus that was filed with the U.S. Securities and Exchange Commission (SEC) on July 1, 2022, and was declared effective on July 15, 2022. Updates and supplementary information regarding the offering will be available on the SEC’s website. Investors can also obtain a copy of the prospectus supplement and the accompanying prospectus from Thinkequity’s office, located at 17 State Street, 41st Floor, New York, New York 10004.
This announcement does not serve as an offer or solicitation to sell or purchase these securities in any state or jurisdiction where such offers would be illegal.
About Cel-SCI Corporation
Cel-SCI believes enhancing a patient’s immune system prior to surgical procedures, radiation, and chemotherapy could significantly improve survival rates. Multikine is intended to specifically target tumors when the immune system is still relatively strong, thereby boosting its ability to combat the tumor effectively.
Multikine (leukocyte interleukin, injection) has been administered to more than 740 patients immediately following diagnosis and surgery. It has received orphan drug designation from the FDA for use as a neoadjuvant therapy in patients with head and neck squamous cell carcinoma.
The company operates near Vienna, Virginia, and Baltimore, Maryland.
Forward-looking statements
This release contains forward-looking statements as defined in the Securities Act of 1933 and the Securities Exchange Act of 1934. Words like “intention,” “believe,” “expect,” “plan,” and similar phrases indicate these types of statements. Such statements involve risks and uncertainties that might cause actual results to differ from what is anticipated. These include, but are not limited to, projected revenue, its intended use, and closing the offering. Factors influencing these results can include challenges in replicating clinical research outcomes, securing timely regulatory approvals, production difficulties, and the need for adequate funding.
* Multikine (Leukocyte Interleukin, Injection) is a registered trademark of CEL-SCI for this clinical therapy. This trademark is subject to FDA evaluation concerning future regulatory submissions for approval. The FDA has not authorized or approved Multikine for sale, barter, or exchange, and its safety or efficacy has not been confirmed.
